

Bibliography

1. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocr Pract.* 2020;26:1-44. <https://doi.org/10.4158/GL-2020-0524SUPPL>
2. Ensrud KE, Black DM, Palermo L, et al. Treatment with Alendronate Prevents Fractures in Women at Highest Risk: Results From the Fracture Intervention Trial. *Arch Intern Med.* 1997;157:2617-24. PMID: 9531231
3. Yusuf AA, Cummings SR, Watts NB, et al. Real-world effectiveness of Osteoporosis Therapies for Fracture Reduction in Post-Menopausal Women. *Arch Osteoporos.* 2018;13:33. DOI: [10.1007/s11657-018-0439-3](https://doi.org/10.1007/s11657-018-0439-3)
4. Black DM, Delmas PD, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. *N Engl J Med.* 2007;356(18):1809-22. DOI: [10.1056/NEJMoa067312](https://doi.org/10.1056/NEJMoa067312)
5. Cummings ST, San Martin J, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. *N Engl J Med.* 2009;361:756-65. DOI: [10.1056/NEJMoa0809493](https://doi.org/10.1056/NEJMoa0809493)
6. Choi, N, Solomon DH, Tsacogianis TN, et al. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients with Osteoporosis: A Cohort Study. *J Bone Miner Res.* 2017;32:611-7. DOI: [10.1002/jbmr.3019](https://doi.org/10.1002/jbmr.3019)
7. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocr Pract.* 2020;26:1-44. <https://doi.org/10.4158/GL-2020-0524SUPPL>
8. Qaseern A, Forciea MA, McLean RM, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med.* 2017;166:818-39. DOI: [10.7326/M15-1361](https://doi.org/10.7326/M15-1361)
9. Eastell R, Rosen, CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol & Metab.* 2019;104:1595-1622. DOI: [10.1210/jc.2019-00221](https://doi.org/10.1210/jc.2019-00221)
10. Adler RA, Fuleihan GE, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2016;31(1):16-35. DOI: [10.1002/jbmr.2708](https://doi.org/10.1002/jbmr.2708)
11. Eastell R, Rosen, CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol & Metab.* 2019;104:1595-1622. DOI: [10.1210/jc.2019-00221](https://doi.org/10.1210/jc.2019-00221)
12. Qaseern A, Forciea MA, McLean RM, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med.* 2017;166:818-39. DOI: [10.7326/M15-1361](https://doi.org/10.7326/M15-1361)
13. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocr Pract.* 2020;26:1-44. <https://doi.org/10.4158/GL-2020-0524SUPPL>
14. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int.* 2014;25(10):2359-81. DOI: [10.1007/s00198-014-2794-2](https://doi.org/10.1007/s00198-014-2794-2)
15. Black DM, Schwartz AV, Ensrud KE, et al. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial. *JAMA.* 2006;296(24):2927-38. DOI: [10.1001/jama.296.24.2927](https://doi.org/10.1001/jama.296.24.2927)
16. Black DM, Reid, IR, Boonen S, et al. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res.* 2012;27(2):243-54. DOI: [10.1002/jbmr.1494](https://doi.org/10.1002/jbmr.1494)
17. American College of Rheumatology. Don't routinely repeat DXA scans more often than once every two years. February 21, 2013. Accessed May 7, 2021. Choosing Wisely website. <https://www.choosingwisely.org/clinician-lists/american-college-rheumatology-routine-repeat-dxa-scans-more-than-once-every-two-years/>
18. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocr Pract.* 2020;26:1-44. <https://doi.org/10.4158/GL-2020-0524SUPPL>
19. Qaseern A, Forciea MA, McLean RM, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. *Ann Intern Med.* 2017;166:818-39. DOI: [10.7326/M15-1361](https://doi.org/10.7326/M15-1361)
20. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int.* 2014;25(10):2359-81. DOI: [10.1007/s00198-014-2794-2](https://doi.org/10.1007/s00198-014-2794-2)

21. Eastell R, Rosen, CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol & Metab.* 2019;104:1595-1622. DOI: [10.1210/jc.2019-00221](https://doi.org/10.1210/jc.2019-00221)

